Who makes Roflumilast alternated days?

Roflumilast alternated days is developed by Fundación Pública Andaluza Progreso y Salud.

What development phase is Roflumilast alternated days in?

Roflumilast alternated days is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Roflumilast alternated days

Fundación Pública Andaluza Progreso y Salud · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Roflumilast alternated days
Also known as	schedule change
Sponsor	Fundación Pública Andaluza Progreso y Salud
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Roflumilast alternated days CI brief — competitive landscape report
Roflumilast alternated days updates RSS · CI watch RSS
Fundación Pública Andaluza Progreso y Salud portfolio CI